Table 1 Demographic and clinical characteristics of the patients in the imaging cohort and biomarker cohort
Imaging cohort | Biomarker cohort | |||||||
|---|---|---|---|---|---|---|---|---|
Total (n = 253) | Non-DM (N = 187) | DM (N = 66) | p-value | Total (n = 100) | Non-DM (N = 73) | DM (N = 27) | p-value | |
Age (years) | 67.7 ± 9.5 | 66.7 ± 10.1 | 70.4 ± 6.8 | 0.001 | 66.6 ± 9.6 | 65.5 ± 9.9 | 69.5 ± 8.2 | 0.064 |
Male | 127 (50.2) | 93 (49.7) | 34 (51.5) | 0.916 | 60 (60.0) | 43 (58.9) | 17 (63.0) | 0.890 |
Hypertension | 151 (59.7) | 103 (55.1) | 48 (72.7) | 0.018 | 58 (58.0) | 39 (53.4) | 19 (70.4) | 0.195 |
Atrial fibrillation | 31 (12.3) | 18 (9.6) | 13 (19.7) | 0.054 | 13 (13.0) | 11 (15.1) | 2 (7.4) | 0.499 |
Stroke | 21 (8.3) | 13 (7.0) | 8 (12.1) | 0.294 | 11 (11.0) | 6 (8.2) | 5 (18.5) | 0.271 |
Ischemic heart disease | 56 (22.1) | 31 (16.6) | 25 (37.9) | 0.001 | 19 (19.0) | 10 (13.7) | 9 (33.3) | 0.053 |
Creatinine (mg/dL) | 0.88 ± 0.23 | 0.86 ± 0.20 | 0.91 ± 0.30 | 0.180 | 1.12 ± 1.37 | 1.07 ± 1.19 | 1.25 ± 1.80 | 0.635 |
Euroscore II | 1.6 ± 1.5 | 1.3 ± 0.7 | 2.5 ± 2.5 | < 0.001 | 1.7 ± 1.8 | 1.7 ± 1.5 | 1.8 ± 2.3 | 0.717 |
NYHA III-IV | 55 (21.8) | 36 (19.4) | 19 (28.8) | 0.155 | 16 (16.0) | 13 (17.8) | 3 (11.1) | 0.614 |
Medication | ||||||||
ACE inhibitor/ARB | 111 (43.9) | 75 (40.1) | 36 (54.5) | 0.059 | 37 (37.0) | 25 (34.2) | 12 (44.4) | 0.481 |
Beta-blocker | 116 (45.8) | 88 (47.1) | 28 (42.4) | 0.613 | 48 (48.0) | 33 (45.2) | 15 (55.6) | 0.487 |
Calcium channel blocker | 56 (22.1) | 43 (23.0) | 13 (19.7) | 0.702 | – | – | – | |
Diuretics | 99 (39.1) | 64 (34.2) | 35 (53.0) | 0.011 | – | – | – | |
Diabetes medication | ||||||||
None | 13 (19.7) | 4 (14.8) | ||||||
Oral medication only | 47 (71.2) | 19 (70.4) | ||||||
Insulin user | 6 (9.1) | 4 (14.8) | ||||||
HbA1c | 5.7 [5.5–5.9] (n = 103) | 6.6 [6.2–7.5] (n = 58) | < 0.001 | 5.8 [5.5–6.0] (n = 64) | 7.0 [6.4–7.4] | < 0.001 | ||
FBS | 109 [96–128] (n = 85) | 132 [110–172] (n = 52) | < 0.001 | 120 [107–147] (n = 25) | ||||